A detailed history of Allspring Global Investments Holdings, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 111,705 shares of KRYS stock, worth $17.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
111,705
Previous 176,446 36.69%
Holding current value
$17.3 Million
Previous $32.4 Million 37.31%
% of portfolio
0.03%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$174.7 - $213.66 $11.3 Million - $13.8 Million
-64,741 Reduced 36.69%
111,705 $20.3 Million
Q2 2024

Jul 26, 2024

BUY
$153.12 - $183.64 $2.76 Million - $3.31 Million
18,021 Added 11.38%
176,446 $32.4 Million
Q1 2024

Apr 18, 2024

BUY
$108.01 - $179.35 $10.7 Million - $17.8 Million
99,101 Added 167.05%
158,425 $28.2 Million
Q4 2023

Jan 25, 2024

BUY
$96.0 - $128.29 $440,448 - $588,594
4,588 Added 8.38%
59,324 $7.36 Million
Q3 2023

Oct 27, 2023

BUY
$108.51 - $130.22 $5.94 Million - $7.13 Million
54,736 New
54,736 $6.35 Million
Q2 2023

Jul 18, 2023

BUY
$78.48 - $130.32 $2,275 - $3,779
29 Added 2.63%
1,130 $132,000
Q1 2023

Apr 13, 2023

BUY
$72.39 - $84.27 $10,134 - $11,797
140 Added 14.57%
1,101 $88,000
Q4 2022

Jan 23, 2023

SELL
$63.14 - $79.9 $1,262 - $1,598
-20 Reduced 2.04%
961 $0
Q3 2022

Oct 26, 2022

BUY
$64.85 - $82.4 $45,978 - $58,421
709 Added 260.66%
981 $68,000
Q2 2022

Jul 25, 2022

SELL
$48.93 - $73.47 $165,774 - $248,916
-3,388 Reduced 92.57%
272 $17,000
Q1 2022

May 02, 2022

BUY
$51.99 - $72.11 $19,548 - $27,113
376 Added 11.45%
3,660 $243,000
Q4 2021

Jan 28, 2022

BUY
$39.81 - $88.24 $130,736 - $289,780
3,284 New
3,284 $229,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.97B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.